Overview

An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
KX-ORAX-008 is an extension study of patients who completed KX-ORAX-007 without disease progression as defined by (RECIST) v 1.1 and who wish to continue Oraxol treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Athenex, Inc.
Collaborator:
PharmaEssentia
Treatments:
Paclitaxel